📈 Novogenia AG · listed on XETRA & the Munich Stock Exchange (m:access) · ISIN DE000A3C35W0

Novogenia AG

Novogenia AG is the stock-listed parent company of Novogenia GmbH.

PERSONALIZED products, services and therapies based on YOUR unique BIOLOGICAL DATA

Novogenia AG harnesses advances in biotechnology and artificial intelligence to create highly personalized solutions from scientific lab-analysis data — spanning genetic testing, personalized supplements and cosmetics, and advanced therapies (personalized infusion therapies and IVF / reproductive genetics). The Group is the listed holding company (ISIN DE000A3C35W0), traded on XETRA and the Munich Stock Exchange.

Visualization of the planned Novogenia AG headquarters and laboratory buildingNew headquarters & laboratory
Company revenue development
€18.2M
▲ +39%
€25.3M
▲ +115%
€54.3M
202320242025
Genetic lab in AustriaFounded in 2009
Stock listedOn the Munich Stock Exchange
In-house productionIn-house lab, supplement & cosmetics manufacturing
Certified qualityISO 9001 · ISO 22000 · ISO 22716 · Medical Genetics License · CLIA
Profitable since 2013Sustained profitability

Our mission

Analyse. Learn. Solve. Explore. — the principle behind every Novogenia product.

Analyse

Using advanced technologies in our laboratories to decypher the human genome and metabolome.

  • Genetic analysis for optimized nutrition
  • Medical genetic analyses incl. pharmacogenetics (medical interpretation by DNA Plus)
  • Virological & diagnostic analyses
  • Genetic analysis for IVF improvement

Learn

Using artificial intelligence to interpret genetic data for insights into the body.

  • AI-powered identification of genetic traits
  • Detect inefficiencies in therapies via lab analytics
  • “Analyse → product → re-analyse” feedback loop
  • Decypher millions of scientific publications

Solve

Based on unique personal data, personalized solutions are produced for each individual.

  • Genetic reports with personalized action plans
  • Personalized supplements & cosmetics
  • Optimized therapies and IVF cycles
  • Personalized drug development as infusions

Explore

Applying the principle of Analyse · Learn · Solve across healthcare and biotechnology.

  • Acquisitions in the healthcare and biotech sector
  • In-house startups to expand the portfolio

Our companies

The operating companies and strategic investments organised under Novogenia AG.

Novogenia AGListed holding company · Munich Stock Exchange
Fully consolidatedOperating subsidiaries
Novogenia GmbHFlagship laboratory & production · Eugendorf, AT100%
NovoMedic GmbHSales to doctors · Eugendorf, AT70%
GENius GmbHSales to pharmacies · Eugendorf, AT67.5%
305Care GmbHB2C cosmetics · Germany85%
HLN-Genetik GmbHClinical genetics laboratory · Austria85%
Mendelio SrlSoftware & bioinformatics · Romania70%
Novogenia Marketing GmbHGroup marketing · Eugendorf, AT100%
Darwin Immobilien GmbHGroup real estate · Austria100%
INOPHA GmbHDrug import & distribution · Germany51%
ChiruTec GmbHMedical devices · Germany51%
Darwin Pharma Holding GmbHDrug & medical-device sub-holding · Munich, DE100%
Held via Darwin Pharma Holding
Medicopharm AGPharmaceutical import · Germany100%
Minority < 10%Financial investments
REVIVIV-therapy & wellness clinics · United Kingdom
GenePlanetConsumer genetics · Ljubljana, SL
Spot Health Inc.Digital health · USA
GenomeLinkDNA-app platform · USA (indirect)
Nephrogen Inc.Gene therapy · USA
100% wholly owned >50% majority-owned, fully consolidated <10% minority financial investment Ownership shown per the audited 2025 consolidated financial statements.

Business segments & companies

All brands & companies →

Three operating divisions — Diagnostics & Personalized Products, Drug Import & Medical Devices, and Minority Investments (€10.6M invested) — plus the Group’s full company org chart and revenue-by-segment charts.

Explore the full Group structure & segments →

Company achievements

An integrated value chain — from laboratory to finished product, largely in house.

In-house laboratory
In-house supplement manufacture
In-house cosmetics manufacture
Profitable since 2013

Our global market

A globally active group — with resellers and customers across the world.

World map highlighting the countries where Novogenia products are sold
16Years of experience in diagnostics

New building & expansion

A €35 million investment in the next decade of capacity.

Visualization of the planned Novogenia AG headquarters and laboratory building
€35 Million InvestmentMove-in: end of 2027

New building & capacity expansion

Novogenia is investing €35 million in a new, state-of-the-art headquarters and laboratory complex — massively expanding diagnostic, supplement and cosmetics production capacity to meet growing demand. The Group expects to move into the new building at the end of 2027.

  • Expanded high-throughput genetic laboratory
  • Scaled in-house supplement & cosmetics manufacturing
  • Automation and additional clean-room capacity
  • Room for the next decade of growth

Inside Novogenia

Tour through the Novogenia Facility

Step inside our Salzburg headquarters — the certified high-throughput genetic and blood laboratory, the in-house supplement and cosmetics manufacturing, and the teams that run the value chain from sample to finished product.

Tour through the Novogenia Facility

Media

Films from the Novogenia Academy — the science behind our analyses and products.

Understanding your body’s instructionsNovogenia Academy
How genes influence which foods are healthy or unhealthy for youNovogenia Academy
How genes influence your body weightNovogenia Academy
Genes and maintaining youthful skinNovogenia Academy
NOVO Academy

Get Certified

NOVO Academy is the group’s online education platform — structured courses, expert talks and certifications on human genetics, personalized nutrition and cosmetics, and how to put DNA-based analysis to work in everyday practice. Built for partners, health professionals and curious customers alike.

  • Genetics & personalized-health fundamentals
  • Certified courses for partners & professionals
  • Expert talks and continuously updated science
Explore NOVO Academy →

Investor & press contact

Questions from shareholders, analysts or media? Our Investor Relations team is happy to help.

investor.relations@novogenia.com